{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:31:04Z","timestamp":1791325864387,"version":"4.3.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009991","name":"Department of Finance of Jilin Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009991","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019714","name":"Foundation Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019714","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Neoadjuvant therapy (NAT) has expanded opportunities to de-escalate axillary surgery in breast cancer, but the appropriate extent of surgery remains uncertain across pretreatment nodal stages and post-treatment responses. This focused narrative review synthesizes evidence from pivotal prospective trials and contemporary observational cohorts on the timing and technical optimization of sentinel lymph node biopsy (SLNB), stage-specific axillary management after NAT, the integration of regional nodal irradiation (RNI), the management of residual low-volume nodal disease, and the potential omission of axillary surgery. In patients with initial cN0 disease, post-NAT SLNB provides pathologic staging, and a negative result may allow axillary lymph node dissection (ALND) to be avoided. In patients with biopsy-proven cN1 disease who convert to ycN0, dual-tracer mapping, retrieval of at least three sentinel lymph nodes, and targeted removal of the previously positive marked node improve diagnostic accuracy and reduce the false-negative rate. However, these diagnostic performance data do not by themselves establish the long-term oncologic safety of omitting ALND. For patients presenting with cN2 disease, ALND remains the standard because prospective evidence supporting SLNB or targeted axillary dissection is limited, although selected patients with HER2-positive or triple-negative breast cancer who achieve an excellent pathologic response may be candidates for prospective de-escalation studies. The NSABP B-51\/RTOG 1304 trial supports consideration of RNI omission in selected patients with initial cN1 disease who convert to ypN0, but it does not demonstrate that radiotherapy can replace ALND. In patients with residual isolated tumor cells or micrometastases, contemporary cohorts show substantial variation in the use of completion ALND and clinically relevant rates of additional nodal involvement, but randomized evidence remains lacking. Complete omission of axillary staging should remain investigational and restricted to carefully selected patients in prospective trials. Future studies should integrate initial nodal burden, residual disease volume, tumor subtype, systemic therapy, and radiotherapy while evaluating recurrence, survival, and treatment-related morbidity. The goal is not de-escalation alone, but identification of the least morbid strategy that preserves reliable staging and durable oncologic control.<\/jats:p>","DOI":"10.3389\/fonc.2026.1910416","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:38:31Z","timestamp":1785321511000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Axillary surgical de-escalation after neoadjuvant therapy in breast cancer: current evidence, clinical controversies, and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Jinxiu","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.03.015","article-title":"Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC","volume":"63","author":"Zheng","year":"2022","journal-title":"Breast"},{"key":"B2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4274\/ejbh.galenos.2024.2023-11-3","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy in cN0 breast cancer: Impact of HER2-positive status on survival","volume":"20","author":"Alors-Ruiz","year":"2024","journal-title":"Eur J Breast Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-5004-7","article-title":"Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: The GANEA 2 study","volume":"173","author":"Classe","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-6090-1","article-title":"Pre-operative axillary ultrasound-guided needle sampling in breast cancer: Comparing the sensitivity of fine needle aspiration cytology and core needle biopsy","volume":"25","author":"Topps","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: Implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000001375","article-title":"Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: Results from ACOSOG Z1071 (Alliance)","volume":"263","author":"Boughey","year":"2016","journal-title":"Ann Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-6270-z","article-title":"Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ILINA trial): A new tool to guide the excision of the clipped node after neoadjuvant treatment","volume":"25","author":"Siso","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004572","article-title":"A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients","volume":"276","author":"Kuemmel","year":"2022","journal-title":"Ann Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.3907","article-title":"Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer","volume":"157","author":"Simons","year":"2022","journal-title":"JAMA Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071539","article-title":"The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer: Systematic review and pooled analysis","volume":"13","author":"Swarnkar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae071","article-title":"Systematic review of targeted axillary dissection in node-positive breast cancer treated with neoadjuvant systemic therapy: Variation in type of marker and timing of placement","volume":"111","author":"de Wild","year":"2024","journal-title":"Br J Surg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41523-026-00984-3","article-title":"Targeted axillary dissection in breast cancer patients: A systematic review and meta-analysis","volume":"12","author":"Abdelaziz","year":"2026","journal-title":"NPJ Breast Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.08.001","article-title":"Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: A systematic review","volume":"45","author":"van Deurzen","year":"2009","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2009.01.026","article-title":"Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis","volume":"16","author":"Kelly","year":"2009","journal-title":"Acad Radiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10549-023-07104-w","article-title":"Long-term outcome in patients with nodal-positive breast cancer treated with sentinel lymph node biopsy alone after neoadjuvant chemotherapy","volume":"203","author":"Lim","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4394","article-title":"Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event","volume":"7","author":"Barrio","year":"2021","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09211-0","article-title":"Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer","volume":"28","author":"Wong","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0044","article-title":"NCCN guidelines insights: Breast cancer, version 1.2017","volume":"15","author":"Gradishar","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103671","article-title":"Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary","volume":"73","author":"Guo","year":"2024","journal-title":"Breast"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07451-2","article-title":"Bias and causal associations in observational research","volume":"359","author":"Grimes","year":"2002","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1245\/s10434-025-18225-5","article-title":"Contemporary trends in axillary surgery for ER-positive, HER2-negative breast cancer stratified by neoadjuvant endocrine therapy, neoadjuvant chemotherapy, or upfront surgery","volume":"33","author":"Douglas","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08888-7","article-title":"How effective is neoadjuvant endocrine therapy (NET) in downstaging the axilla and achieving breast-conserving surgery","volume":"27","author":"Montagna","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09073-6","article-title":"Axillary management after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer","volume":"28","author":"Kantor","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414859","article-title":"Omitting regional nodal irradiation after response to neoadjuvant chemotherapy","volume":"392","author":"Mamounas","year":"2025","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.06.032","article-title":"Postmastectomy radiation therapy following pathologic complete nodal response to neoadjuvant chemotherapy: A prelude to NSABP B-51","volume":"162","author":"Haque","year":"2021","journal-title":"Radiother Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-10830-4","article-title":"Is axillary radiation not inferior to axillary dissection for sentinel lymph node-positive breast cancer after neoadjuvant chemotherapy","volume":"29","author":"Khan","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01052","article-title":"Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): The OPBC-05\/ICARO study","volume":"43","author":"Montagna","year":"2025","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(25)00598-4","article-title":"Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07\/microNAC): An international, retrospective cohort study","volume":"27","author":"Montagna","year":"2026","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1167912","article-title":"The nodal positivity rate in breast pCR patients with initially, clinically node-negative breast cancer after neoadjuvant systemic therapy: A systematic review and meta-analysis","volume":"13","author":"Ma","year":"2023","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2017.0562","article-title":"Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery","volume":"152","author":"Tadros","year":"2017","journal-title":"JAMA Surg"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123698","article-title":"Avoiding axillary sentinel lymph node biopsy after neoadjuvant systemic therapy in breast cancer: Rationale for the prospective, multicentric EUBREAST-01 trial","volume":"12","author":"Reimer","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.01.002","article-title":"Omission of axillary sentinel lymph node biopsy in early invasive breast cancer","volume":"67","author":"Reimer","year":"2023","journal-title":"Breast"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70190","article-title":"Optimizing the integration of modern systemic therapies and advanced radiotherapy techniques in breast cancer management: An expert opinion from the Institut Curie Breast Radiotherapy Group","volume":"158","author":"Cheptea","year":"2026","journal-title":"Int J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-16973-y","article-title":"Oncologic outcomes with de-escalation of axillary surgery after neoadjuvant chemotherapy for breast cancer: Results from > 1500 patients on the I-SPY2 clinical trial","volume":"32","author":"Boughey","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103700","article-title":"2023 year in review: Early breast cancer","volume":"74","author":"Nader-Marta","year":"2024","journal-title":"Breast"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020192534","article-title":"Axillary nodal evaluation in breast cancer: State of the art","volume":"295","author":"Chang","year":"2020","journal-title":"Radiology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1148\/radiol.12110853","article-title":"Performance of FDG PET\/CT in the clinical management of breast cancer","volume":"266","author":"Groheux","year":"2013","journal-title":"Radiology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41523-023-00551-0","article-title":"Multigene profiles to guide the use of neoadjuvant chemotherapy for breast cancer: A Copenhagen Breast Cancer Genomics Study","volume":"9","author":"Jensen","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.acra.2024.07.052","article-title":"Delta radiomics based on MRI for predicting axillary lymph node pathologic complete response after neoadjuvant chemotherapy in breast cancer patients","volume":"32","author":"Mao","year":"2025","journal-title":"Acad Radiol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znaf125","article-title":"BJS commission on the surgical management of the axilla in breast cancer","volume":"112","author":"Boland","year":"2025","journal-title":"Br J Surg"},{"key":"B45","unstructured":"Breast Surgical Oncology Fellowship Curriculum and Minimum Training Requirements\n          \n          \n          \n          2025"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910416\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:38:32Z","timestamp":1785321512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1910416\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":45,"alternative-id":["10.3389\/fonc.2026.1910416"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1910416","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1910416"}}